44 results on '"Davis DMR"'
Search Results
2. A case of diagnostic uncertainty: High-grade melanocytoma versus balloon cell melanoma in a pediatric patient.
- Author
-
Shimshak S, Sokumbi O, Guo R, Davis DMR, Geiersbach KB, and Comfere NI
- Subjects
- Humans, Female, Child, Diagnosis, Differential, Melanocytes pathology, Melanoma diagnosis, Melanoma pathology, Skin Neoplasms pathology, Skin Neoplasms diagnosis, Nevus, Pigmented pathology, Nevus, Pigmented diagnosis
- Abstract
An 11-year-old female was referred from an outside institution after a diagnostic biopsy and subsequent excision of a progressively enlarging reddish-brown nodule demonstrated features concerning for a balloon cell nevus with severe atypia versus a high-grade melanocytoma. Upon review of the initial biopsy specimen and molecular data, we favored the diagnosis to be consistent with a high-grade melanocytoma with balloon cell changes while considering the possibility of balloon cell melanoma due to concerning histopathologic and genetic abnormalities. In this case study, we discuss critical diagnostic considerations in this rare pediatric case and highlight important pathologic and clinical features of melanocytomas and balloon cell melanoma., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
3. Delay in diagnosis and undertreatment of lichen sclerosus in pediatric male patients: A retrospective case series.
- Author
-
Ge A, Reinhart JP, Davis DMR, Tollefson MM, Torgerson RR, Mancini AJ, and Aghazadeh Mohandesi N
- Abstract
Competing Interests: Conflicts of interest None declared.
- Published
- 2024
- Full Text
- View/download PDF
4. Adult-onset linear IgA bullous dermatosis: a retrospective single-center cohort study of 81 patients and literature review.
- Author
-
Wang KL, Lehman JS, Todd A, and Davis DMR
- Subjects
- Adult, Female, Humans, Male, Age of Onset, Drug Eruptions etiology, Drug Eruptions diagnosis, Drug Eruptions epidemiology, Inflammatory Bowel Diseases complications, Inflammatory Bowel Diseases drug therapy, Neoplasms complications, Paraneoplastic Syndromes immunology, Paraneoplastic Syndromes diagnosis, Paraneoplastic Syndromes etiology, Recurrence, Retrospective Studies, Linear IgA Bullous Dermatosis diagnosis, Linear IgA Bullous Dermatosis drug therapy, Linear IgA Bullous Dermatosis epidemiology
- Abstract
Background: Linear IgA bullous dermatosis (LABD) is a rare autoimmune blistering disorder that may be drug-induced or paraneoplastic. We aim to characterize features of LABD and determine differentiating factors among idiopathic, drug-induced, or malignancy-associated diseases., Methods: We conducted a single-center retrospective chart review of adult patients with linear IgA bullous dermatosis at a large tertiary referral center and a literature review of adult linear IgA bullous dermatosis., Results: Eighty-one patients were included in the study. Ten patients (12.3%) had comorbid malignancy and nine (11.1%) had inflammatory bowel disease. Median disease duration was significantly shorter in both drug-induced (1.2 vs. 48.8 months; P < 0.001) and malignancy-associated (1.7 vs. 48.8 months; P < 0.001) LABD compared with idiopathic LABD. Recurrent episodes occurred significantly more often in idiopathic LABD compared to those with drug-induced (76.1 vs. 11.5%; P < 0.001) or malignancy-associated disease (76.1 vs. 33.3%; P = 0.019). Time to diagnosis was significantly shorter in the drug-induced (0.2 vs. 5.4 months; P < 0.001) and malignancy-associated groups (0.7 vs. 5.4 months; P = 0.049) compared with idiopathic; similarly, time to improvement was significantly shorter in both drug-induced (0.4 vs. 3.0 months; P < 0.001) and malignancy-associated disease (1.1 vs. 3.0 months; P = 0.016). Clinical morphology was indistinguishable between groups. Limitations included retrospective data collection, data from tertiary referral centers, and limited racial and ethnic diversity., Conclusion: Screening for underlying malignancy, as well as for a predisposing medication or possibly inflammatory bowel disease, may be advisable in patients with LABD, particularly when it is newly diagnosed., (© 2024 the International Society of Dermatology.)
- Published
- 2024
- Full Text
- View/download PDF
5. Linear IgA bullous dermatosis of childhood: Retrospective single-center cohort.
- Author
-
Wang KL, Lehman JS, and Davis DMR
- Subjects
- Humans, Retrospective Studies, Male, Female, Child, Child, Preschool, Adolescent, Infant, Linear IgA Bullous Dermatosis drug therapy, Linear IgA Bullous Dermatosis diagnosis, Linear IgA Bullous Dermatosis pathology
- Abstract
Linear IgA bullous dermatosis (LABD) is a rare autoimmune blistering disorder impacting children and adults. In this single-center retrospective chart review of pediatric patients with LABD at a large tertiary referral center, we report the unifying and unique clinical features of 10 pediatric patients. Patients typically presented with the "cluster of jewels" sign (n = 6; 60%), mucous membrane involvement (n = 5; 50%) and had a mean disease duration of 38 months; six patients (60%) required inpatient admission for management of their skin disease, including all five patients who had mucous membrane involvement. Our findings suggest that pediatric LABD may be a disease with high morbidity and may be associated with severe complications when mucous membranes are involved., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
6. Updates in Dermatology.
- Author
-
Tollefson MM and Davis DMR
- Subjects
- Humans, Dermatology, Skin Neoplasms
- Published
- 2024
- Full Text
- View/download PDF
7. Executive summary: Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.
- Author
-
Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Eichenfield LF, Frazer-Green L, Paller AS, Schwarzenberger K, Silverberg JI, Singh AM, Wu PA, and Sidbury R
- Subjects
- Adult, Humans, Cyclosporine therapeutic use, Immunosuppressive Agents therapeutic use, Methotrexate therapeutic use, Phototherapy, Dermatitis, Atopic drug therapy
- Abstract
Background: The summarized guidelines update the 2014 recommendations for the management of AD with phototherapy and systemic therapies., Methods: A multidisciplinary workgroup conducted a systematic review and applied the GRADE approach for assessing the certainty of the evidence and formulating and grading recommendations., Results: The workgroup developed 11 recommendations on the management of AD in adults with phototherapy and systemic therapies, including biologics, oral Janus Kinase inhibitors, and other immunomodulatory medications., Conclusions: The evidence supported strong recommendations for the use of dupilumab, tralokinumab, abrocitinib, baricitinib, and upadacitinib and conditional recommendations in favor of using phototherapy, azathioprine, cyclosporine, methotrexate, and mycophenolate, and against the use of systemic corticosteroids., Competing Interests: Conflict of interest The American Academy of Dermatology (AAD) strives to produce clinical guidelines that reflect the best available evidence supplemented with the judgment of expert clinicians. Significant efforts are taken to minimize the potential for conflicts of interest to influence guideline content. The management of conflict of interest for this guideline complies with the Council of Medical Specialty Societies' Code of Interactions with Companies. Funding of guideline production by medical or pharmaceutical entities is prohibited, full disclosure is obtained and evaluated for all guideline contributors throughout the guideline development process, and recusal is used to manage identified relationships. The AAD conflict of interest policy summary may be viewed at www.aad.org., (Copyright © 2023 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
8. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.
- Author
-
Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Eichenfield LF, Frazer-Green L, Paller AS, Schwarzenberger K, Silverberg JI, Singh AM, Wu PA, and Sidbury R
- Subjects
- Adult, Humans, Cyclosporine therapeutic use, Immunosuppressive Agents therapeutic use, Methotrexate therapeutic use, Phototherapy, Dermatitis, Atopic drug therapy, Janus Kinase Inhibitors therapeutic use
- Abstract
Background: For people with atopic dermatitis (AD) refractory to topical therapies, treatment with phototherapy and systemic therapies can be considered. Multiple biologic therapies and Janus kinase (JAK)inhibitors have been approved since 2014 to treat AD. These guidelines update the 2014 recommendations for management of AD with phototherapy and systemic therapies., Objective: To provide evidence-based recommendations on the use of phototherapy and systemic therapies for AD in adults., Methods: A multidisciplinary workgroup conducted a systematic review and applied the GRADE approach for assessing the certainty of evidence and formulating and grading recommendations., Results: The workgroup developed 11 recommendations on the management of AD in adults with phototherapy and systemic agents, including biologics, oral JAK inhibitors, and other immunomodulatory medications., Limitations: Most randomized controlled trials of phototherapy and systemic therapies for AD are of short duration with subsequent extension studies, limiting comparative long-term efficacy and safety conclusions., Conclusions: We make strong recommendations for the use of dupilumab, tralokinumab, abrocitinib, baricitinib, and upadacitinib. We make conditional recommendations in favor of using phototherapy, azathioprine, cyclosporine, methotrexate, and mycophenolate, and against the use of systemic corticosteroids., Competing Interests: Conflicts of interest Dr Drucker receives research grants paid to his institution from the National Eczema Association, Eczema Society of Canada, Canadian Dermatology Foundation, Canadian Institutes for Health Research, US National Institutes of Health, and Physician Services Incorporated Foundation. Dr Cohen serves on the board of directors for Timber and Evommune receiving stock options and/or fees; as a consultant for Asana Biosciences, Ferndale Laboratories, Inc, Novartis, Facilitation of International Dermatology Education, Dermavant Sciences, Leo Pharma, Inc, UCB, and Cosmetic Ingredient Review receiving honoraria and/or stock options. Dr Eichenfield serves on the board of directors for Forte Biosciences and Verrica Pharmaceuticals, Inc, receiving honoraria and/or stock options; as an investigator for AbbVie, Arcutis, Dermavant, Galderma Laboratories, Pfizer, and Bausch receiving research grants, fees, and/or honoraria; as a consultant for AbbVie, Almirall, Arcutis, Asana, Dermavant, Eli Lilly, Galderma, Ichnos/Glenmark, Incyte, Janssen, Leo Pharma, Novartis, Ortho Dermatologics, Otsuka, Pfizer, Regeneron, and Sanofi Genzyme, honoraria; as an independent contractor for Elsevier, Inc receiving royalties. Dr Paller serves as a consultant for Abbvie, Abeona, Almirall, Amagma, Anaptysbio, Arena, Bausch, Bristol Myer Squibb, Dermavant, Dermira, Eli Lilly, Exicure, Forte, Leo, Lifemax, Novartis, Phoenix, Pierre Fabre, Pfizer, Rapt, Regeneron, Sanofi, Sol-Gel, UCB, and Venthera receiving honoraria; as an investigator for Anaptysbio, Eli Lilly, Incyte, Janssen, Krystal Bio, Lenus, Regeneron, and UCB receiving no compensation. Dr Schwarzenberger is the founder of Pretel, Inc and serves as a data safety monitoring board member for Pfizer, Inc receiving fees. Dr Sidbury serves as an advisory board member for Pfizer, Inc receiving honoraria; as a principal investigator for Regeneron receiving grants and research funding; as an investigator for Brickell Biotech, Inc, and Galderma USA receiving grants and research funding; as a consultant for Galderma Global and Microes receiving fees or no compensation. Dr Silverberg serves as an advisory board member for BioMX, Boehringer Ingelheim, RAPT Therapeutics, Celgene, Ortho Dermatologics, TARGET Pharma, AFYX Therapeutics, Corrona, Inc, Dermira, Pfizer, Inc, Leo Pharma, Inc, and Menlo Therapeutics receiving honoraria and/or fees; as an investigator for DS Pharma, TARGET Pharma, Kiniksa Pharmaceuticals, Ltd, Menlo Therapeutics, GlaxoSmithKline, AbbVie, Leo Pharma, Inc, and Regeneron receiving research funding, honoraria, or no compensation; as a consultant for AOBiome, Bluefin Biomedicine, Bodewell, BiomX, Inc, Galderma Research & Development, LLC, Arena Pharmaceuticals, Dermavant Sciences, Incyte Corporation, DS Biopharma, Sun Pharmaceutical Industries, Ltd, AnaptysBio, Asana Biosciences, LLC, Pfizer, Inc, Glenmark Generics, Inc, Sanofi, Kiniksa Pharmaceuticals, Ltd, GlaxoSmithKlein, Eli Lilly and Company, AbbVie, Regeneron, and Medimmune receiving honoraria or fees; as a speaker for the Fall Clinical Dermatology Conference, Maui Derm, and Regeneron receiving honoraria or fees. Dr Singh serves as an advisory board member for Incyte receiving honoraria. DR Wu is an author for UpToDate, Inc receiving honoraria. Dr Davis, Dr Alikhan, Dr Bercovitch, Athor Darr, and Dr Frazer-Green have no conflicts of interest to declare., (Copyright © 2023 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
9. Pemphigoid gestationis and polymorphic eruption of pregnancy: treatment and outcomes in a retrospective cohort study.
- Author
-
Xie F, Lehman JS, Baban F, Johnson EF, Theiler RN, Todd A, and Davis DMR
- Subjects
- Pregnancy, Female, Humans, Retrospective Studies, Treatment Outcome, Pemphigoid Gestationis diagnosis, Pemphigoid Gestationis drug therapy, Pregnancy Complications diagnosis, Pregnancy Complications drug therapy, Exanthema
- Published
- 2024
- Full Text
- View/download PDF
10. Updates on the dermatopathology of pregnancy-associated skin conditions.
- Author
-
Xie F, Agrawal S, Johnson EF, Wieland CN, Davis DMR, Theiler RN, and Lehman JS
- Abstract
Pathologists provide valuable input in the dermatological care of pregnant patients in various contexts. This article provides dermatopathology updates on cutaneous changes associated with pregnancy, organized based on the following classification system: physiological skin changes in pregnancy, specific dermatoses of pregnancy, dermatoses modified in pregnancy, and skin neoplasms in pregnancy. Awareness of the impact of pregnancy on the skin by pathologists is important, as this is an opportunity to contribute to diagnostic precision in this patient population., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
11. Use of a pregnancy dermatology clinical scoring system to differentiate between pemphigoid gestationis and polymorphic eruption of pregnancy: practical considerations for the obstetrician.
- Author
-
Xie F, Davis DMR, Baban F, Johnson EF, Theiler RN, Todd A, Pruneddu S, Murase JE, Maul JT, Ambros-Rudolph CM, and Lehman JS
- Subjects
- Pregnancy, Female, Humans, Obstetricians, Pemphigoid Gestationis diagnosis, Dermatology, Pregnancy Complications diagnosis
- Published
- 2023
- Full Text
- View/download PDF
12. An update on long-term outcomes of pediatric follicular mucinosis over a 20-year period: a retrospective cohort study.
- Author
-
Jin MF, Ali NS, Davis DMR, Johnson EF, and Gibson LE
- Subjects
- Humans, Child, Retrospective Studies, Skin pathology, Cell Transformation, Neoplastic pathology, Mucinosis, Follicular diagnosis, Skin Neoplasms pathology, Mycosis Fungoides diagnosis, Mycosis Fungoides therapy, Mycosis Fungoides pathology
- Abstract
Background: Follicular mucinosis (FM) is a rare disease characterized by mucin accumulation in the follicular unit. FM's etiology is still widely debated since its first description in 1957. Follicular mucinosis is usually reported to be benign in children, although reports of malignant transformation, most commonly mycosis fungoides, exist. The present project aims to demonstrate that children with a diagnosis of follicular mucinosis have positive long-term outcomes and do not develop mycosis fungoides., Materials and Methods: This is a retrospective cohort study where patients with a diagnosis of follicular mucinosis ages 22 years and below were identified. Data surrounding the patient's diagnosis of FM, differential diagnosis, treatments, and long-term outcomes were collected. Patients who were lost to follow-up were contacted by phone for an update on the status of their skin and overall health., Results: Out of 14 patients with follow-up information, none developed subsequent mycosis fungoides or other hematologic malignancies., Conclusion: Pediatric patients with follicular mucinosis will likely present with limited disease and not experience malignant transformation., (© 2023 the International Society of Dermatology.)
- Published
- 2023
- Full Text
- View/download PDF
13. Guidelines of care for the management of atopic dermatitis in adults with topical therapies.
- Author
-
Sidbury R, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Drucker AM, Eichenfield LF, Frazer-Green L, Paller AS, Schwarzenberger K, Silverberg JI, Singh AM, Wu PA, and Davis DMR
- Subjects
- Adult, Humans, Calcineurin Inhibitors therapeutic use, Administration, Topical, Glucocorticoids therapeutic use, Histamine Antagonists therapeutic use, Dermatitis, Atopic drug therapy, Dermatologic Agents therapeutic use, Anti-Infective Agents, Local therapeutic use
- Abstract
Background: New evidence has emerged since the 2014 guidelines that further informs the management of atopic dermatitis (AD) with topical therapies. These guidelines update the 2014 recommendations for management of AD with topical therapies., Objective: To provide evidence-based recommendations related to management of AD in adults using topical treatments., Methods: A multidisciplinary workgroup conducted a systematic review and applied the GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) approach for assessing the certainty of evidence and formulating and grading recommendations., Results: The workgroup developed 12 recommendations on the management of AD in adults with topical therapies, including nonprescription agents and prescription topical corticosteroids (TCS), calcineurin inhibitors (TCIs), Janus kinase (JAK) inhibitors, phosphodiesterase-4 inhibitors (PDE-4), antimicrobials, and antihistamines., Limitations: The pragmatic decision to limit the literature review to English-language randomized trials may have excluded data published in other languages and relevant long-term follow-up data., Conclusions: Strong recommendations are made for the use of moisturizers, TCIs, TCS, and topical PDE-4 and JAK inhibitors. Conditional recommendations are made for the use of bathing and wet wrap therapy and against the use of topical antimicrobials, antiseptics, and antihistamines., Competing Interests: Conflicts of interest David E. Cohen∗, MD, MPH serves on the board of directors for Timber and Evommune receiving stock options and/or fees and as a consultant for Asana Biosciences, Ferndale Laboratories, Inc, Novartis, Facilitation of International Dermatology Education, Dermavant Sciences, Leo Pharma, Inc, UCB, and Cosmetic Ingredient Review receiving honoraria and/or stock options. Lawrence F. Eichenfield∗, MD serves on the board of directors for Forte Biosciences and Verrica Pharmaceuticals, Inc, receiving honoraria and/or stock options; as an investigator for Abbvie, Arcutis, Dermavant, Galderma Laboratories, Pfizer, and Bausch, receiving research grants, fees, and/or honoraria; as a consultant for Abbvie, Almirall, Arcutis, Asana, Dermavant, Eli Lilly, Galderma, Ichnos/Glenmark, Incyte, Janssen, Leo Pharma, Novartis, Ortho Dermatologics, Otsuka, Pfizer, Regeneron, and Sanofi Genzyme, honoraria; and as an independent contractor for Elsevier, Inc receiving royalties. Amy S. Paller∗, MD serves as a consultant for Abbvie, Abeona, Almirall, Amagma, Anaptysbio, Arena, Bausch, Bristol Myer Squibb, Dermavant, Dermira, Eli Lilly, Exicure, Forte, Leo, Lifemax, Novartis, Phoenix, Pierre Fabre, Pfizer, Rapt, Regeneron, Sanofi, Sol-Gel, UCB, and Venthera receiving honoraria; and as an investigator for Anaptysbio, Eli Lilly, Incyte, Janssen, Krystal Bio, Lenus, Regeneron, and UCB receiving no compensation. Kathryn Schwarzenberger, MD is the founder of Pretel, Inc and serves as a data safety monitoring board member for Pfizer, Inc receiving fees. Robert Sidbury∗, MD serves as an advisory board member for Pfizer, Inc receiving honoraria; as a principal investigator for Regeneron receiving grants and research funding; as an investigator for Brickell Biotech, Inc, and Galderma USA receiving grants and research funding; and as a consultant for Galderma Global and Microes receiving fees or no compensation. Jonathan I. Silverberg∗, MD, PhD, MPH serves as an advisory board memberfor BioMX, Boehringer Ingelheim, RAPT Therapeutics, Celgene, Ortho Dermatologics, TARGET Pharma, AFYX Therapeutics, Corrona, Inc, Dermira, Pfizer, Inc, Leo Pharma, Inc, and Menlo Therapeutics receiving honoraria and/or fees; as an investigator for DS Pharma, TARGET Pharma, Kiniksa Pharmaceuticals, Ltd, Menlo Therapeutics, GlaxoSmithKline, AbbVie, Leo Pharma, Inc, and Regeneron receiving research funding, honoraria, or no compensation; as a consultant for AOBiome, Bluefin Biomedicine, Bodewell, BiomX, Inc, Galderma Research & Development, LLC., Arena Pharmaceuticals, Dermavant Sciences, Incyte Corporation, DS Biopharma, Sun Pharmaceutical Industries, Ltd, AnaptysBio, Asana Biosciences, LLC., Pfizer, Inc, Glenmark Generics, Inc, Sanofi, Kiniksa Pharmaceuticals, Ltd, GlaxoSmithKlein, Eli Lilly and Company, AbbVie, Regeneron, and Medimmune receiving honoraria or fees; and as a speaker for the Fall Clinical Dermatology Conference, Maui Derm, and Regeneron receiving honoraria or fees. Anne Marie Singh, MD as a consultant for Abbvie. Peggy Wu, MD serves as an author for UpToDate, Inc receiving honoraria. Drs. Alikhan, Bercovitch, Davis, and Frazer-Green, and Jennifer M. Darr, LCSW have no relationships to disclose., (Copyright © 2023 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
14. Executive summary: American Academy of Dermatology guidelines of care for the management of atopic dermatitis in adults with topical therapies.
- Author
-
Sidbury R, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Drucker AM, Eichenfield LF, Frazer-Green L, Paller AS, Schwarzenberger K, Silverberg JI, Singh AM, Wu PA, and Davis DMR
- Subjects
- Adult, Humans, Calcineurin Inhibitors therapeutic use, Glucocorticoids, Dermatitis, Atopic drug therapy, Dermatology, Dermatologic Agents therapeutic use
- Abstract
These guidelines update the 2014 recommendations for management of atopic dermatitis in adults with topical therapies. A multidisciplinary workgroup employed best practices for guideline development, including a systematic review of the evidence and application of the Grading of Recommendations, Assessment, Development, and Evaluation approach for assessing the certainty of the evidence and formulating and grading recommendations. The evidence on atopic dermatitis treatment supported strong recommendations for the use of nonprescription moisturizers, topical calcineurin inhibitors, topical corticosteroids, and topical PDE-4 and JAK inhibitors. Conditional recommendations are made for the use of bathing and wet wrap therapy and against the use of topical antimicrobials, antiseptics, and antihistamines., Competing Interests: Conflict of Interest The American Academy of Dermatology (AAD) strives to produce clinical guidelines that reflect the best available evidence supplemented with the judgment of expert clinicians. Significant efforts are taken to minimize the potential for conflicts of interest to influence guideline content. The management of conflict of interest for this guideline complies with the Council of Medical Specialty Societies' Code of Interactions with Companies. Funding of guideline production by medical or pharmaceutical entities is prohibited, full disclosure is obtained and evaluated for all guideline contributors throughout the guideline development process, and recusal is used to manage identified relationships. The AAD conflict of interest policy summary may be viewed at www.aad.org., (Copyright © 2023 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
15. Development and multicenter international validation of a diagnostic tool to differentiate between pemphigoid gestationis and polymorphic eruption of pregnancy.
- Author
-
Xie F, Davis DMR, Baban F, Johnson EF, Theiler RN, Todd A, Pruneddu S, Murase JE, Maul JT, Ambros-Rudolph CM, and Lehman JS
- Subjects
- Female, Pregnancy, Humans, Retrospective Studies, Pruritus diagnosis, Pemphigoid Gestationis diagnosis, Pregnancy Complications diagnosis, Exanthema
- Abstract
Background: Pemphigoid gestationis (PG) and polymorphic eruption of pregnancy (PEP) may be similar morphologically but confer different maternal and fetal risks. Direct immunofluorescence is the gold standard test used to differentiate between the 2 diagnoses but is not always available., Objective: To develop and validate a clinical scoring system to differentiate PG from PEP., Methods: After developing a scoring system based on differentiating clinical factors reported in existing literature, we tested its diagnostic accuracy in a retrospective international multicenter validation study in collaboration with the European Academy of Dermatology and Venereology's Skin Diseases in Pregnancy Taskforce., Results: Nineteen pregnancies (16 patients) affected by PG and 39 pregnancies (39 patients) affected by PEP met inclusion criteria. PG had a mean score of 4.6 (SD, 2.5) and PEP had a mean score of -0.3 (SD, 2.0). The area under the curve was 0.93 (95% CI, 0.86-1.00). Univariate analysis revealed that almost all criteria used in the scoring system were significantly different between the groups (P < .05), except for skip pregnancy and multiple gestations, which were then removed from the final scoring system., Limitations: Small retrospective study., Conclusion: The Pregnancy Dermatoses Clinical Scoring System may be useful to differentiate PG from PEP in resource-limited settings., Competing Interests: Conflicts of interest Dr Murase has served as an advisor for LeoPharma, Sanofi-Genzyme, Eli Lilly, Regeneron, and UCB and has given disease-state nonbranded talks for Regeneron and UCB. Dr Maul is an employee of USZ and has served as an advisor and/or received speaking fees and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, BMS, Celgene, Eli Lilly, LEO Pharma, Janssen-Cilag, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, UCB. Dr Lehman has served on the advisory board of Argenx. Other authors have no conflicts of interest to declare., (Copyright © 2023 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
16. Pemphigoid gestationis and polymorphic eruption of pregnancy in skin of color.
- Author
-
Xie F, Sominidi-Damodaran S, Cantwell HM, Wyles SP, Wieland CN, Comfere NI, Davis DMR, and Lehman JS
- Subjects
- Female, Humans, Pregnancy, Skin, Ethnic and Racial Minorities, Pemphigoid Gestationis diagnosis, Pemphigoid Gestationis drug therapy, Pregnancy Complications diagnosis
- Published
- 2023
- Full Text
- View/download PDF
17. Pediatric lichen planus: A single-center retrospective review of 26 patients with follow up.
- Author
-
Mohandesi NA, Berry NA, Tollefson MM, Lehman JS, and Davis DMR
- Subjects
- Adult, Female, Humans, Child, Adolescent, Young Adult, Male, Follow-Up Studies, Retrospective Studies, Adrenal Cortex Hormones therapeutic use, Lichen Planus diagnosis, Lichen Planus drug therapy, Lichen Planus pathology, Lichen Planus, Oral diagnosis, Lichen Planus, Oral drug therapy
- Abstract
Background/objectives: Pediatric lichen planus (LP) is rare with variable prevalence and atypical presentations compared to adults. Data on LP are lacking for the pediatric population in the United States. We present demographics, presentations, and treatments for a pediatric LP cohort., Methods: We reviewed 26 patients diagnosed with LP at 20 years or younger. Treatment responses were defined as no response, partial response, and complete response., Results: Demographics included 54% females and median diagnosis age of 16 years (range 6-20). Most patients presented with cutaneous LP (65%), with fewer having associated oral (23%), nail (7.7%), or genital (3.8%) involvement. Some had cutaneous-only LP (38%) or strictly mucosal LP (oral-only 19% and genital-only 15%). LP lesions were pruritic (50%), painful (19%), and/or asymptomatic (35%). Complete/partial responses occurred with medium-potency topical corticosteroids in cutaneous (n = 7; 64%), oral (n = 3; 75%), and genital LP (n = 3; 100%), with high/ultra-high potency topical corticosteroids in oral LP (n = 6; 86%), and with topical calcineurin inhibitors in genital LP (n = 2; 100%). Side effects were clobetasol-related oral candidiasis and biopsy-related penile depressed scar. Most patients with available follow-up achieved remission (n = 17; 81%)., Conclusions: Pediatric LP usually presents in adolescence with cutaneous involvement and is symptomatic. However, patients frequently can have oral, genital, or nail lesions or may be asymptomatic, so they need thorough examinations and follow-up. Long-term remission is common due to treatment or natural disease course. Medium-potency corticosteroids are recommended for cutaneous, oral, and genital LP. Various other local and systemic therapies exist with successful treatment responses., (© 2022 Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
18. An investigation of metabolic disturbances, including urinary stone disease, hypothyroidism, and osteoporosis in basal cell nevus syndrome.
- Author
-
Schlaht KM, Sas DJ, Davis DMR, and Hand JL
- Subjects
- Adult, Child, Humans, Retrospective Studies, Basal Cell Nevus Syndrome complications, Hypothyroidism complications, Hypothyroidism epidemiology, Osteoporosis complications, Osteoporosis epidemiology, Skin Neoplasms diagnosis, Urinary Calculi complications, Urologic Diseases
- Abstract
Background/objectives: Basal cell nevus syndrome (BCNS) is an autosomal dominant skin cancer predisposition syndrome associated with abnormal mineral metabolism, a risk factor for urinary stone disease (USD). However, no research investigating the association between BCNS and USD or other manifestations of abnormal mineral metabolism has been conducted. The objective of this study is to investigate the association between BCNS and conditions associated with disordered mineral metabolism including USD, hypothyroidism, and osteoporosis and compare them to prevalence in the general population to elucidate potential unknown manifestations of the condition., Methods: This retrospective study examined medical records of adult and pediatric patients with confirmed BCNS from the Mayo Clinic database from 1 January 1995 to 12 January 2020. Records were surveyed for evidence of USD and other comorbidities potentially related to BCNS. The studied cohort included 100 adult patients and 5 pediatric patients., Results: A total of 105 patients were included in this analysis, 10 of whom experienced confirmed USD, representing a prevalence of 10%. Six adult patients were identified with a diagnosis of osteoporosis, representing a prevalence of 6%. Thirteen adult patients were identified with a diagnosis of hypothyroidism, representing a prevalence of 13%., Conclusions: This study identified a prevalence of USD in BCNS patients comparable to estimates of national prevalence, indicating that known abnormalities in mineral metabolism likely do not increase the incidence of USD in BCNS patients. Additional findings included increased prevalence of hypothyroidism and decreased prevalence of osteoporosis in the BCNS cohort compared to national averages., (© 2022 Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
19. Association between topical corticosteroid use and fracture risk among pediatric patients with atopic dermatitis.
- Author
-
Imhof RL, Weaver AL, St Sauver J, Hand J, Davis DMR, and Tollefson MM
- Subjects
- Administration, Topical, Adrenal Cortex Hormones adverse effects, Child, Glucocorticoids adverse effects, Humans, Dermatitis, Atopic drug therapy, Dermatitis, Atopic epidemiology, Dermatologic Agents therapeutic use
- Abstract
Competing Interests: Conflicts of interest None disclosed.
- Published
- 2022
- Full Text
- View/download PDF
20. Autoimmune progesterone dermatitis: a retrospective case series.
- Author
-
Aghazadeh N, Berry NA, Torgerson RR, Park MA, and Davis DMR
- Abstract
Autoimmune progesterone dermatitis (APD) is a rare hypersensitivity disorder characterized by recurring dermatologic manifestations during the luteal phase of the menstrual cycle in women. Well-defined clinical and diagnostic criteria, outcomes measurements, and standard treatments are lacking., Methods: We performed a single-institution retrospective review of adult patients (older than 20 years at the time of diagnosis) with APD., Results: Fourteen patients were included with mean age of clinical onset of 34.3 ± 7.7 (range 24-54) years. There was a delay of 3.9 ± 5.5 (range 0.4-20) years between the onset of disease symptoms and diagnosis. The onset of APD was after exposure to exogenous progesterone in 9 of 14 patients. Progesterone skin test was performed in 9 patients and 6 were positive. Patients frequently presented with urticaria (9/14, 64.3%) and dermatitis (4/14, 28.6%). Continuous combined oral contraceptives (4/14, 28.6%), gonadotropin-releasing hormone agonist (3/14, 21.4%), and hysterectomy with bilateral salpingo-oophorectomy (2/14, 14.3%) were the most common attempted treatments with reliable outcomes., Conclusions: APD is a rare disorder which lacks universal diagnostic measures and criteria, contributing to a significant delay in diagnosis. Large-scale multicenter studies are needed to develop accurate tests, establish diagnostic criteria, and define treatment outcomes., Competing Interests: None., (Copyright © 2022 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of Women’s Dermatologic Society.)
- Published
- 2022
- Full Text
- View/download PDF
21. American Academy of Dermatology Guidelines: Awareness of comorbidities associated with atopic dermatitis in adults.
- Author
-
Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Eichenfield LF, Frazer-Green L, Paller AS, Silverberg JI, Singh AM, and Sidbury R
- Subjects
- Adult, Comorbidity, Humans, United States epidemiology, Dermatitis, Atopic diagnosis, Dermatitis, Atopic epidemiology, Dermatology, Metabolic Syndrome diagnosis, Metabolic Syndrome epidemiology, Myocardial Infarction
- Abstract
Background: Studies found associations between atopic dermatitis (AD) and various comorbidities., Objective: To appraise evidence of the association between AD and comorbidities among adults., Methods: Our multidisciplinary work group conducted a systematic review of the association between AD and selected comorbidities. We applied the Grading of Recommendations, Assessment, Development, and Evaluation for prognosis approach for assessing the certainty of the evidence, providing statements of association based on the available evidence., Results: Analysis of the evidence resulted in 32 statements. Clear evidence of the association of AD in adults and select allergic, atopic, immune-mediated mental health and bone health conditions and skin infections was identified. There is some evidence supporting an association between AD and substance use, attention deficit hyperactivity disorder, and elements of metabolic syndrome. Evidence suggests a small association with various cardiovascular conditions. The association between AD in adults and autism spectrum disorders, myocardial infarction, stroke, and metabolic syndrome is inconclusive., Limitations: This analysis is based on the best available evidence at the time it was conducted. This guideline does not make recommendations for screening or management of comorbidities in adults with AD., Conclusions: Clinicians should be aware of comorbidities associated with AD. Further research is needed to determine whether screening or management of comorbidities is beneficial for adults with AD., (Copyright © 2022 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
22. A 28-year single institution experience with primary skin malignancies in the pediatric population.
- Author
-
Kuruoglu D, Weissler JM, Bustos SS, Moran SL, Davis DMR, Bite U, Mardini S, Baum CL, Otley CC, Brewer JD, Lehman JS, and Sharaf B
- Subjects
- Child, Humans, Retrospective Studies, Skin, Carcinoma, Basal Cell, Melanoma epidemiology, Skin Neoplasms
- Abstract
The aim of this study is to report our institution's experience with pediatric skin malignancies. A single institution retrospective review of pediatric patients with a primary skin malignancy from 1992 to 2020 was performed. Demographics, tumor characteristics and treatment outcomes were reviewed. Ninety-nine patients with 109 primary malignant skin lesions were reviewed. The most common lesion was malignant melanoma [MM] ( n = 50, 45.9%). Compared to non-melanoma skin cancer (NMSC), MM were more likely to present on trunk or extremities ( p =.01, OR = 3.2), and be misdiagnosed ( p =.03, OR = 2.7). NMSC were more common in the head and neck region ( p =.01, OR = 3.2), and were associated with a personal history of skin cancer ( p =.0005, OR = 17.1) or a known risk factor ( p =.04, OR = 2.5). Patients with MM were 12.4-times more likely to develop metastatic disease compared to NMSC ( p <.0001). Increased Breslow's thickness also increased the odds of developing metastatic disease ( p =.03, OR = 1.6 per 1-mm increase). Interval time between lesion recognition and diagnostic biopsy or surgical treatment did not impact overall survival. Malignant melanoma was the most common malignancy in our cohort, followed by basal cell carcinoma. Malignant melanoma was the most likely tumor to be misdiagnosed and/or metastasize. Treatment delays did not impact risk of metastasis, recurrence or survival rate, though some patients succumbed to disease. These results may be attributed to small sample size or the biology of melanoma in pediatric patients. Awareness of skin malignancies in the pediatric population is imperative to providers and the public, with low threshold for specialty consultation and excision when warranted.
- Published
- 2022
- Full Text
- View/download PDF
23. Dermatologic Manifestations of Systemic Diseases in Childhood.
- Author
-
Quddusi FI, Youssef MJ, and Davis DMR
- Abstract
Competing Interests: AUTHOR DISCLOSURE Drs Quddusi, Youssef, and Davis have no financial relationships relevant to this article. This commentary does not contain a discussion of an unapproved/investigative use of a commercial product/device.
- Published
- 2021
- Full Text
- View/download PDF
24. Trends in utilization of non-first-line topical acne medications among children, adolescents, and adults in the United States, 2012-2016.
- Author
-
Afarideh M, Rodriguez Baisi KE, Davis DMR, Hand JL, and Tollefson MM
- Subjects
- Adolescent, Adult, Child, Health Care Surveys, Humans, Infant, Newborn, Salicylic Acid, United States, Zinc, Acne Vulgaris drug therapy
- Abstract
Background/objective: Current knowledge about usage of effective, but non-first-line topical acne medications in the United States is limited. We aimed to investigate utilization patterns and temporal trends for such acne medications in the US ambulatory care., Methods: Pediatric (≤18 years old) and adult (>18 years old) data from the 2012 to 2016 (inclusive) cycles of the US National Ambulatory Medical Care Survey were extracted. Utilization patterns of six non-first-line topical acne medications (ie, azelaic acid, salicylic acid, glycolic acid, sulfur, resorcinol, and zinc) were compared and followed over time., Results: Data from 218 410 US office-based sampled visits during 2012-2016 were included in the analysis. Across all acne visits (n = 1542), salicylic acid (1.58%), azelaic acid (1.22%), and glycolic acid (0.52%) were the most frequently used agents, while zinc and resorcinol were not used. Sulfur (0.52%) and salicylic acid (0.33%) were the only medications used in preadolescents, and none of these medications were used in the neonatal or infantile group. Temporal trends for using at least one of these medications were insignificant among both pediatric and adult age groups (P = .825 and .136, respectively)., Conclusions: Salicylic acid and azelaic acid are the most frequently used of the studied second-line medications to treat acne, although the use of these and the other non-first-line topical medications overall is uncommon, especially among younger groups of US pediatric patients., (© 2021 Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
25. Sucking Bruises in Infancy: A Mimicker of Child Abuse.
- Author
-
Quddusi FI, Vasquez A, Gregory S, Davis DMR, and Derauf DC
- Subjects
- Child, Humans, Infant, Physical Abuse, Child Abuse diagnosis, Contusions diagnosis, Contusions etiology
- Published
- 2021
- Full Text
- View/download PDF
26. Bundled intervention to improve patient safety by reducing skin specimen-related errors in a tertiary dermatology practice.
- Author
-
Privalle AN, Davis DMR, Tollefson MM, Doppler JM, Welder S, Morris-Kidd JA, Peterson BS, and Comfere NI
- Subjects
- Biopsy methods, Humans, Outcome Assessment, Health Care, Quality Improvement, Software, Specimen Handling, Workflow, Biopsy standards, Dermatology standards, Medical Errors prevention & control, Patient Care Bundles standards, Skin pathology
- Published
- 2021
- Full Text
- View/download PDF
27. Autoimmune progesterone dermatitis in the adolescent population.
- Author
-
Aghazadeh N, Chattha AJ, Hartz MF, and Davis DMR
- Subjects
- Adolescent, Adult, Child, Female, Humans, Progesterone adverse effects, Retrospective Studies, Young Adult, Autoimmune Diseases diagnosis, Autoimmune Diseases drug therapy, Dermatitis diagnosis, Dermatitis drug therapy, Dermatitis epidemiology, Urticaria
- Abstract
Background/objective: Autoimmune progesterone dermatitis (APD) is a rare autoimmune hypersensitivity reaction that occurs cyclically at the peak of endogenous progesterone production during the menstrual cycle in women. No study characterizing APD in the adolescent population is found; it appears likely to be underdiagnosed and undertreated., Methods: A retrospective, single-center, review of all adolescent and pediatric patients (<20 years old at onset) with documented diagnosis of APD., Results: Seventeen adolescent APD patients were included (mean age at diagnosis: 14.4 ± 2 years, mean interval of 13.6 ± 11.1 months between symptom onset and diagnosis). Twelve patients presented with urticaria, two with fixed drug eruption. Erythema multiforme, eczema, and recurrent aphthous stomatitis were present in one patient each. Exposure to exogenous progestin was present in two patients prior to disease onset. Progesterone skin test was performed in six patients with positive results in two. Fourteen patients received antihistamines and/or a topical corticosteroid. Combined oral contraceptives (COCs) were given to eleven patients, in seven via continuous daily dosing. Gonadotropin-releasing hormone agonist (GnRHa) was used in five, progesterone desensitization in four, omalizumab in two, and danazol in one patient., Conclusions: Adolescent APD is associated with a significant delay in diagnosis. The most common manifestation is urticaria. Exogenous exposure to progestins is uncommon in adolescent APD. Continuous COC, GnRHa, and progesterone desensitization have been used to control symptoms. Large, multicenter studies are required to better define, diagnose, and treat this under recognized condition among adolescent patients., (© 2020 Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
28. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.
- Author
-
Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Siegel M, Stoff B, Strober B, Wu JJ, Hariharan V, and Menter A
- Subjects
- Academies and Institutes standards, Administration, Cutaneous, Combined Modality Therapy methods, Combined Modality Therapy standards, Complementary Therapies standards, Dermatology standards, Evidence-Based Medicine methods, Evidence-Based Medicine standards, Foundations standards, Humans, Patient Education as Topic standards, Psoriasis diagnosis, Severity of Illness Index, Treatment Outcome, United States, Complementary Therapies methods, Dermatologic Agents administration & dosage, Dermatology methods, Psoriasis therapy
- Abstract
Psoriasis is a chronic, inflammatory, multisystem disease that affects up to 3.2% of the United States population. This guideline addresses important clinical questions that arise in psoriasis management and care and provides recommendations based on the available evidence. The treatment of psoriasis with topical agents and with alternative medicine will be reviewed, emphasizing treatment recommendations and the role of dermatologists in monitoring and educating patients regarding benefits as well as risks that may be associated. This guideline will also address the severity assessment methods of psoriasis in adults., (Copyright © 2020 American Academy of Dermatology, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
29. The anatomic distribution of isolated and syndrome-associated port-wine stain.
- Author
-
Elias AJ, Hand JL, Tollefson MM, and Davis DMR
- Subjects
- Adolescent, Child, Female, Humans, Male, Retrospective Studies, Hemangioma, Capillary, Klippel-Trenaunay-Weber Syndrome complications, Klippel-Trenaunay-Weber Syndrome diagnosis, Klippel-Trenaunay-Weber Syndrome epidemiology, Port-Wine Stain epidemiology, Sturge-Weber Syndrome complications, Sturge-Weber Syndrome epidemiology, Vascular Diseases
- Abstract
Background/objectives: To determine the role of sex in port-wine stain (PWS) distribution and describe the epidemiologic and anatomic differences between syndrome-associated and non-syndrome-associated PWS using modern criteria., Methods: A retrospective review of PWS patients aged 18 years and younger from 1995 to 2018 seen in the Department of Dermatology at an academic tertiary referral center. Cases were reviewed for sex, anatomic location, and presence of associated syndrome. 4,527 records were reviewed on the basis of ICD billing codes for congenital vascular malformations, with 516 meeting inclusion criteria., Results: 516 patients were included in the analysis: 234 (45.4%) men and 282 (54.6%) women. A female preponderance of Sturge-Weber syndrome (18 of 23, 78%, P = .03) and a trend toward more female-isolated PWS (149 of 269, 55%, P = .72) were found. No lateral predominance observed for isolated PWS was found: 112(41.6%) limited left-side lesions and 113(42%) limited right-side lesions (P = .41). A trend toward Klippel-Trenaunay syndrome (KTS)-associated PWS occurring more commonly isolated to the left side (76 (45.5%) vs 59 (35.12%) P = .29) was found. Nine percent of SWS patients had a PWS on the body. Five percent of KTS patients had a facial PWS. The lower limb was the most common location overall of body PWS with 33.8% of isolated PWS and 81.5% of KTS patients having a lower limb lesion., Conclusions: Female children were more likely to be diagnosed with SWS, and a trend toward more isolated PWS in women was found. No lateral predominance of isolated PWS was found, but KTS-associated PWS was more common on the left. A considerable proportion of lesions do not appear in anatomic locations traditionally considered typical in the setting of associated syndromes, which underscores the importance of conducting a complete physical examination and adhering to diagnostic criteria for those syndromes., (© 2020 Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
30. Use of spironolactone to treat acne in adolescent females.
- Author
-
Roberts EE, Nowsheen S, Davis DMR, Hand JL, Tollefson MM, and Wetter DA
- Subjects
- Adolescent, Adult, Child, Female, Humans, Minnesota, Retrospective Studies, Treatment Outcome, Young Adult, Acne Vulgaris drug therapy, Spironolactone adverse effects
- Abstract
Background/objectives: Studies assessing the utility of spironolactone for treating acne in adolescent females are lacking. Thus, we sought to examine spironolactone's role in treating this patient population., Methods: A retrospective review was performed to determine the efficacy of spironolactone treatment in adolescent females seen at Mayo Clinic in Rochester, Minnesota, from 2007 to 2017., Results: In a cohort of 80 pediatric patients with a median age of 19 years (range, 14-20 years), 64 patients (80%) experienced improvement of acne on treatment with spironolactone (median dose, 100 mg daily) with a favorable side effect profile. Approximately a quarter of patients (22.5%) had a complete response; more than half (58.8%) had a complete response or a partial response greater than 50%. Initial and maximal responses were observed at a median of 3 months and 5 months, respectively. Patients received treatment with spironolactone for a median duration of 7 months (range, 3-45 months) with limited side effects., Conclusions: Spironolactone demonstrated efficacy in treating acne in adolescent females and is a safe long-term alternative to systemic antibiotics in these patients., (© 2020 Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
31. Hair Loss.
- Author
-
Imhof RL, Davis DMR, and Tollefson MM
- Subjects
- Humans, Alopecia diagnosis, Alopecia etiology, Hair
- Abstract
Competing Interests: AUTHOR DISCLOSUREMr Imhof and Drs Davis and Tollefson have disclosed no financial relationships relevant to this article. This commentary does not contain a discussion of an unapproved/investigative use of a commercial product/device.
- Published
- 2020
- Full Text
- View/download PDF
32. Drug reaction with eosinophilia and systemic symptoms (DRESS) in the pediatric population: A systematic review of the literature.
- Author
-
Kim GY, Anderson KR, Davis DMR, Hand JL, and Tollefson MM
- Subjects
- Child, Humans, Drug Hypersensitivity Syndrome complications, Drug Hypersensitivity Syndrome diagnosis, Drug Hypersensitivity Syndrome drug therapy
- Abstract
Background: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a drug-induced hypersensitivity reaction that can have fatal complications. Although substantial data exist regarding DRESS in adults, to our knowledge, a systematic review of available literature has not been performed in children., Objective: To review available data on DRESS in the pediatric population., Methods: A systematic literature review was performed for pediatric (aged <18 years) patients with DRESS., Results: We included 82 articles with 148 patients; of these, 97.9% experienced a skin rash, and the liver was the second most common organ involved (84.5%). Among 143 patients for which a treatment regimen was reported, 85.3% were treated with systemic steroids. Intravenous immunoglobulin alone failed to improve symptoms in 5 patients who were initially misdiagnosed, whereas those treated with intravenous immunoglobulin and steroids (2.7%) showed rapid clinical improvement. The mortality rate was low (3.0%). Complications included multiorgan failure and acute respiratory distress syndrome., Limitations: Limitations included limited availability of data for statistical analysis., Conclusion: Pediatric DRESS commonly involves the liver. With treatment, the prognosis is commonly good, but serious complications may occur. Corticosteroids, possibly in conjunction with intravenous immunoglobulin in severe cases, may serve as an effective, valuable treatment of pediatric DRESS., (Copyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
33. Surgical management of pseudoainhum in loricrin keratoderma.
- Author
-
Singh K, Crum OM, Davis DMR, Moran SL, and Hand JL
- Published
- 2020
- Full Text
- View/download PDF
34. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.
- Author
-
Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Prater EF, Rahimi RS, Rupani RN, Siegel M, Stoff B, Strober BE, Tapper EB, Wong EB, Wu JJ, Hariharan V, and Elmets CA
- Subjects
- Acitretin therapeutic use, Cyclosporine therapeutic use, Drug Monitoring, Humans, Methotrexate therapeutic use, Piperidines therapeutic use, Pyrimidines therapeutic use, Thalidomide analogs & derivatives, Thalidomide therapeutic use, Psoriasis drug therapy
- Abstract
Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 2% of the world's population. In this guideline, we focus the discussion on systemic, nonbiologic medications for the treatment of this disease. We provide detailed discussion of efficacy and safety for the most commonly used medications, including methotrexate, cyclosporine, and acitretin, and provide recommendations to assist prescribers in initiating and managing patients on these treatments. Additionally, we discuss newer therapies, including tofacitinib and apremilast, and briefly touch on a number of other medications, including fumaric acid esters (used outside the United States) and therapies that are no longer widely used for the treatment of psoriasis (ie, hydroxyurea, leflunomide, mycophenolate mofetil, thioguanine, and tacrolimus)., (Copyright © 2020 American Academy of Dermatology, Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
35. Oral erosions associated with surreptitious marijuana vaping in an adolescent boy.
- Author
-
Ali NS, Billings ML, Tollefson MM, Davis DMR, and Hand JL
- Subjects
- Adolescent, Humans, Male, Marijuana Smoking adverse effects, Oral Ulcer etiology, Oral Ulcer pathology, Vaping adverse effects
- Abstract
A 15-year-old boy presented with painful ulcerations affecting the oral mucosa that were eventually attributed to marijuana vaping. In this case report, we highlight cannabis vaping as a potential cause of oral erosions due to injury and chronic inflammation of the oral mucosa., (© 2020 Wiley Periodicals, Inc.)
- Published
- 2020
- Full Text
- View/download PDF
36. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.
- Author
-
Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, Connor C, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Parra SL, Pathy AL, Farley Prater EA, Rupani RN, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, and Elmets CA
- Subjects
- Adolescent, Adrenal Cortex Hormones therapeutic use, Anthralin therapeutic use, Calcineurin Inhibitors therapeutic use, Cardiovascular Diseases epidemiology, Child, Child, Preschool, Coal Tar therapeutic use, Comorbidity, Cyclosporine therapeutic use, Dyslipidemias epidemiology, Evidence-Based Medicine, Humans, Infant, Infant, Newborn, Inflammatory Bowel Diseases epidemiology, Insulin Resistance, Mental Health, Metabolic Syndrome epidemiology, Nicotinic Acids therapeutic use, Obesity epidemiology, Psoriasis psychology, Retinoids therapeutic use, Biological Products therapeutic use, Dermatologic Agents therapeutic use, Methotrexate therapeutic use, Photochemotherapy, Psoriasis drug therapy, Psoriasis epidemiology
- Abstract
Psoriasis is a chronic, multisystem, inflammatory disease that affects approximately 1% of children, with onset most common during adolescence. This guideline addresses important clinical questions that arise in psoriasis management and provides evidence-based recommendations. Attention will be given to pediatric patients with psoriasis, recognizing the unique physiology, pharmacokinetics, and patient-parent-provider interactions of patients younger than 18 years old. The topics reviewed here mirror those discussed in the adult guideline sections, excluding those topics that are irrelevant to, or lack sufficient information for, pediatric patients., (Copyright © 2019 American Academy of Dermatology, Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
37. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy.
- Author
-
Elmets CA, Lim HW, Stoff B, Connor C, Cordoro KM, Lebwohl M, Armstrong AW, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Leonardi CL, Lichten J, Mehta NN, Paller AS, Parra SL, Pathy AL, Farley Prater EA, Rupani RN, Siegel M, Strober BE, Wong EB, Wu JJ, Hariharan V, and Menter A
- Subjects
- Academies and Institutes standards, Foundations standards, Humans, Meta-Analysis as Topic, Phototherapy instrumentation, Phototherapy methods, Systematic Reviews as Topic, Treatment Outcome, United States, Dermatology standards, Phototherapy standards, Practice Guidelines as Topic, Psoriasis therapy
- Abstract
Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 3.2% of the world's population. In this section of the guidelines of care for psoriasis, we will focus the discussion on ultraviolet (UV) light-based therapies, which include narrowband and broadband UVB, UVA in conjunction with photosensitizing agents, targeted UVB treatments such as with an excimer laser, and several other modalities and variations of these core phototherapies, including newer applications of pulsed dye lasers, intense pulse light, and light-emitting electrodes. We will provide an in-depth, evidence-based discussion of efficacy and safety for each treatment modality and provide recommendations and guidance for the use of these therapies alone or in conjunction with other topical and/or systemic psoriasis treatments., (Copyright © 2019 American Academy of Dermatology, Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
38. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
- Author
-
Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, and Elmets CA
- Subjects
- Adalimumab therapeutic use, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Biosimilar Pharmaceuticals therapeutic use, Certolizumab Pegol therapeutic use, Drug Therapy, Combination, Etanercept therapeutic use, Evidence-Based Medicine, Humans, Infliximab therapeutic use, Piperidines therapeutic use, Pyrimidines therapeutic use, Pyrroles therapeutic use, Ustekinumab therapeutic use, Biological Products therapeutic use, Dermatologic Agents therapeutic use, Psoriasis drug therapy
- Abstract
Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US population. This guideline addresses important clinical questions that arise in psoriasis management and care, providing recommendations based on the available evidence. The treatment of psoriasis with biologic agents will be reviewed, emphasizing treatment recommendations and the role of the dermatologist in monitoring and educating patients regarding benefits as well as associated risks., (Copyright © 2018 American Academy of Dermatology, Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
39. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.
- Author
-
Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, and Menter A
- Subjects
- Arthritis, Psoriatic diagnosis, Arthritis, Psoriatic epidemiology, Comorbidity, Dyslipidemias epidemiology, Evidence-Based Medicine, Humans, Hypertension epidemiology, Inflammatory Bowel Diseases epidemiology, Kidney Diseases epidemiology, Life Style, Liver Diseases epidemiology, Lung Diseases, Obstructive epidemiology, Neoplasms epidemiology, Patient Education as Topic, Psoriasis therapy, Sleep Apnea Syndromes epidemiology, Cardiovascular Diseases epidemiology, Mental Health, Metabolic Syndrome epidemiology, Obesity epidemiology, Physician's Role, Psoriasis epidemiology, Psoriasis psychology, Quality of Life
- Abstract
Psoriasis is a chronic, inflammatory, multisystem disease that affects up to 3.2% of the US population. This guideline addresses important clinical questions that arise in psoriasis management and care, providing recommendations on the basis of available evidence., (Copyright © 2018 American Academy of Dermatology, Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
40. Temporal trends in prenatal risk factors for the development of infantile hemangiomas.
- Author
-
Schoch JJ, Hunjan MK, Anderson KR, Lohse CM, Hand JL, Davis DMR, and Tollefson MM
- Subjects
- Adult, Female, Hemangioma epidemiology, Humans, Incidence, Infant, Infant, Newborn, Pregnancy, Pregnancy Complications epidemiology, Risk Factors, Hemangioma etiology
- Abstract
Background/objectives: Specific maternal risk factors have recently been identified in the development of infantile hemangiomas (IH), including gestational diabetes (GDM), maternal antihypertensive medication use or gestational hypertension (GHTN), maternal progesterone use, and artificial reproductive technologies (ART). We sought to explore the change in incidence of these risk factors over time and determine their association with the increased incidence of hemangiomas over 35 years, as previously reported., Methods: The charts of 869 mother and infant pairs (infants previously diagnosed with IH between January 1, 1976, and December 31, 2010) were reviewed for prenatal complications. Rates of the prenatal complications over the 35-year period in birth mothers of infants diagnosed with IH were determined and evaluated by year of diagnosis (1976-1990, 1991-2000, and 2001-2010)., Results: Over the 35-year period in which the incidence of IH was previously examined, maternal age at delivery, prepregnancy body mass index (BMI), use of ART, maternal progesterone use, placental abnormalities, and GDM also increased., Conclusions: GDM, ART, and maternal progesterone use increased over the past 35 years, mirroring the previously reported trend of increasing incidence of IH. Maternal age and BMI also increased in mothers of infants with IH. Further exploration of this association may direct future research in the pathogenesis of infantile hemangiomas., (© 2018 Wiley Periodicals, Inc.)
- Published
- 2018
- Full Text
- View/download PDF
41. Association between atopic dermatitis and squamous cell carcinoma: a case-control study.
- Author
-
Cho JM, Davis DMR, Wetter DA, Bartley AC, and Brewer JD
- Subjects
- Aged, Aged, 80 and over, Case-Control Studies, Female, Humans, Male, Middle Aged, Minnesota epidemiology, Retrospective Studies, Risk Assessment, Carcinoma, Squamous Cell epidemiology, Dermatitis, Atopic epidemiology, Skin Neoplasms epidemiology
- Abstract
Background: Conflicting data have been published on whether an association exists between atopic dermatitis (AD) and nonmelanoma skin cancer. This study aimed to determine whether individuals with AD had an increased risk of squamous cell carcinoma (SCC) development., Methods: We conducted a retrospective, case-control study of patients residing in Olmsted County, Minnesota. Cases were selected from patients seen at Mayo Clinic (Rochester, Minnesota) who had an initial SCC diagnosis (either invasive SCC or SCC in situ) from January 1, 1996, through December 23, 2010. Age- and sex-matched controls were selected from patients seen at Mayo Clinic with no history of SCC before the case event date., Results: Three hundred ninety-nine individuals with a documented history of SCC were identified and matched with 780 controls who did not have a history of SCC. After adjusting for race, smoking history, ionizing radiation exposure, corticosteroid and cyclosporine use, and non-SCC skin cancers, the odds ratio for SCC development between patients with history of AD versus patients without history of AD was 1.75 (95% CI, 1.05-2.93)., Conclusions: Our findings support an increased risk of SCC development in the setting of AD., (© 2017 The International Society of Dermatology.)
- Published
- 2018
- Full Text
- View/download PDF
42. Orthopedic complications of linear morphea: Implications for early interdisciplinary care.
- Author
-
Schoch JJ, Schoch BS, Werthel JD, McIntosh AL, and Davis DMR
- Subjects
- Adolescent, Child, Child, Preschool, Extremities pathology, Female, Humans, Male, Musculoskeletal Diseases epidemiology, Musculoskeletal Diseases surgery, Orthopedic Procedures statistics & numerical data, Patient Care Team, Retrospective Studies, Scleroderma, Localized drug therapy, Musculoskeletal Diseases etiology, Scleroderma, Localized complications
- Abstract
Linear morphea of the limb primarily affects children, and extracutaneous manifestations are common. Orthopedic surgeons are often essential in the care of patients with linear morphea, yet there are few reports outlining specific orthopedic complications in this population. We sought to improve the understanding of orthopedic complications in linear morphea of the limb. Between 1999 and 2014, 51 children were evaluated for linear morphea of an extremity. Twenty-six (51%) had documented orthopedic manifestations. Outcome measures included limb length discrepancy, angular malalignment, limb atrophy, and orthopedic surgical intervention. Joint contractures were most common, affecting 88% of patients, followed by limb atrophy, angular deformity, and limb length discrepancy; 14% required surgical intervention. Despite the use of systemic immunosuppressive therapy in many patients, approximately half of patients with linear morphea of an extremity have orthopedic disease. Early orthopedist involvement is crucial to improve limb alignment and preserve function., (© 2017 Wiley Periodicals, Inc.)
- Published
- 2018
- Full Text
- View/download PDF
43. Associations of self-reported allergic diseases and musculoskeletal problems in children: A US population-based study.
- Author
-
Barrick BJ, Jalan S, Tollefson MM, Milbrandt TA, Larson AN, Rank MA, Lohse CM, and Davis DMR
- Subjects
- Adolescent, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Self Report, Surveys and Questionnaires, Asthma epidemiology, Bone Diseases epidemiology, Eczema epidemiology, Food Hypersensitivity epidemiology, Joint Diseases epidemiology, Musculoskeletal Diseases epidemiology, Rhinitis, Allergic, Seasonal epidemiology
- Abstract
Background: Previous studies have found increased rates of musculoskeletal problems in adults with allergic disease, but whether this association holds true for children is unknown., Objective: To investigate the association of bone, joint, and muscle problems in children with a history of allergic disease., Methods: Data were obtained from the 2007 Child and Adolescent Health Measurement Initiative. Univariable and multivariable logistic regression models accounting for the sampling design were used to evaluate associations of bone, joint, and muscle problems with allergic diseases, such as asthma, hay fever, food allergies, and eczema. Associations were summarized with odds ratios (ORs) and 95% confidence intervals (CIs)., Results: The survey included 91,642 individuals aged 0 to 17 years. Multivariable modeling found statistically significant associations between the number of allergic diseases and bone, joint, and muscle problems (1 allergic disease: adjusted OR, 1.28; 95% CI, 1.04-1.56; P = .02; 2 allergic diseases: adjusted OR, 2.55; 95% CI, 1.92-3.39; P < .001; 3 allergic diseases: adjusted OR, 2.70; 95% CI, 1.88-3.86; P < .001; and 4 allergic diseases: adjusted OR, 4.35; 95% CI, 2.46-7.69; P < .001). Severe eczema (but not mild eczema) was associated with bone, joint, and muscle problems (adjusted OR, 2.81; 95% CI, 1.64-4.81; P < .001) and with bone problems (adjusted OR, 6.08; 95% CI, 1.94-19.12; P = .002)., Conclusion: Self-reported allergic diseases in children were associated with bone, joint, and muscle problems, and associations strengthened with allergic disease severity and number of allergic diseases. Severe eczema may be associated with bone problems in children. Bone, joint, and muscle problems must be considered in children with severe allergic disease, and prospective studies are necessary to define this association., (Copyright © 2017 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
44. Prenatal Risk Factors for Infantile Hemangioma Development.
- Author
-
Hunjan MK, Schoch JJ, Anderson KR, Lohse CM, Marnach ML, Hand JL, Davis DMR, and Tollefson MM
- Subjects
- Diabetes, Gestational, Female, Humans, Male, Maternal Exposure adverse effects, Pre-Eclampsia, Pregnancy, Pregnancy Complications, Risk Factors, Hemangioma etiology
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.